You are here

Acasti Pharma Recognized in TSX Venture Exchange’s 2019 Venture 50

LAVAL, Quebec, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announces it has been recognized  by the TSX Venture Exchange  in its “2019 Venture 50,” a ranking of the strongest companies on TSX Venture Exchange by share price, trading volume and market capitalization.
Thursday, February 21, 2019 - 09:15